FDA approves vaccine to fight prostate cancer

The Food and Drug Administration on Thursday approved the first treatment that uses a so-called cancer vaccine, a drug that trains the body’s own immune system to fight the disease.

The drug, Provenge, developed by the Dendreon Corporation, was approved to treat advanced prostate cancer. In clinical trials it extended the lives of patients about four months compared with a placebo.

[New York Times]